A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE in combination with Dexamethasone or VELCADE in combination with Dexamethasone and Cyclophosphamide or VELCADE in combination with Dexamethasone and Lenalidomide in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after Primary Therapy for Multiple Myeloma and have achieved stable disease after 4 cycles of VELCADE/Dexamethasone therapy

Trial Profile

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE in combination with Dexamethasone or VELCADE in combination with Dexamethasone and Cyclophosphamide or VELCADE in combination with Dexamethasone and Lenalidomide in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after Primary Therapy for Multiple Myeloma and have achieved stable disease after 4 cycles of VELCADE/Dexamethasone therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Bortezomib; Cyclophosphamide; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms SEQUENTIAL
  • Most Recent Events

    • 07 Jun 2012 Actual patient number is 163 according to ClinicalTrials.gov.
    • 07 Jun 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top